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Abstract
Macrophages are important effectors in the clearance of antibody-coated tumor cells. However, the signaling pathways that
regulate macrophage-induced ADCC are poorly defined. To understand the regulation of macrophage-mediated ADCC, we
used human B cell lymphoma coated with Rituximab as the tumor target and murine macrophages primed with IFNc as the
effectors. Our data demonstrate that the PtdIns 3-kinase/Akt pathway is activated during macrophage-induced ADCC and
that the inhibition of PtdIns 3-kinase results in the inhibition of macrophage-mediated cytotoxicity. Interestingly,
downstream of PtdIns 3-kinase, expression of constitutively active Akt (Myr-Akt) in macrophages significantly enhanced
their ability to mediate ADCC. Further analysis revealed that in this model, macrophage-mediated ADCC is dependent upon
the release of nitric oxide (NO). However, the PtdIns 3-kinase/Akt pathway does not appear to regulate NO production. An
examination of the role of the PtdIns 3-kinase/Akt pathway in regulating conjugate formation indicated that macrophages
treated with an inhibitor of PtdIns 3-kinase fail to polarize the cytoskeleton at the synapse and show a significant reduction
in the number of conjugates formed with tumor targets. Further, inhibition of PtdIns 3-kinase also reduced macrophage
spreading on Rituximab-coated surfaces. On the other hand, Myr-Akt expressing macrophages displayed a significantly
greater ability to form conjugates with tumor cells. Taken together, these findings illustrate that the PtdIns 3-kinase/Akt
pathway plays a critical role in macrophage ADCC through its influence on conjugate formation between macrophages and
antibody-coated tumor cells.
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Introduction
In recent years, monoclonal antibodies such as rituximab and
alemtuzumab [1] have emerged as effective therapeutic agents in
the treatment of human malignancies. Although several mecha-
nisms have been proposed for the elimination of tumor cells during
antibody therapy, the engagement of Fcc receptors on immune
effector cells plays a dominant role in the clearance of tumor cells
during antibody therapy [2]. The population of immune cells that
bear Fcc receptors include monocytes/macrophages, neutrophils
and NK cells. However, in a murine model, Uchida et al
demonstrated that macrophages are the principal mediators of
CD20 antibody-dependent depletion of B cells [3]. There are
three classes of FccR expressed by human and murine
macrophages: FccRI, FccRIIb and FccRIII. FccRI and RIII
are activating receptors while FccRIIb is an inhibitory receptor. In
addition, human macrophages express FccRIIa while murine cells
express FccRIV, both of which are activating receptors [4–6].
The mechanism by which macrophages cause the cytolysis of
tumor cells depends on the nature of the target tumor cell. Several
studies have reported the release of TNFa and nitric oxide (NO) as
dominant mediators of macrophage induced cytotoxicity [7–11],
although the release of certain proteases [12] and reactive oxygen
species (ROS) by macrophages has also been reported in few cases
[13]. The activation of macrophages for cytolytic function involves
a priming event during which macrophages acquire the ability to
respond to tumor cells upon subsequent exposure. IFNc is a potent
inducer of macrophage tumoricidal activity [14–16]. The priming
of macrophages with IFNc leads to the up-regulation of Fcc
receptors, TNFa, and inducible nitric oxide synthase (iNOS); all of
which can enhance the killing of tumor cells [16,17]. To this end,
the administration of ex-vivo IFNc-activated macrophages is being
tested as an approach to augment traditional cancer therapies
[18,19].
The signaling pathways involved in NK cell-mediated cytotox-
icity have been extensively studied and the activation of protein
tyrosine kinases such as lck and Syk kinase are shown to be the
initial signaling events in NK cells [20,21]. The stimulation of both
PtdIns 3-kinase and extracellular signal regulatory kinase 1/2 (Erk
1/2) has been shown to play a critical role during NK cell-
mediated cytotoxicity [22,23]. Erk 1/2 control the lytic function of
NK cells by regulating the movement of cytosolic perforin and
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been shown that Erk 1/2 activation is independent of the
traditional Ras-dependent pathway and that PtdIns 3-kinaseinase
mediates the activation of Erk 1/2 through sequential involve-
ment of Rac1, PAK1 and MEK [22]. In addition, although the
release of cytotoxic granules containing perforin and granzymes
by NK cells mediates the lysis of tumor cell, an efficient conjugate
formation between the NK cell and the target tumor cell is
critical for the process of cytotoxicity [24,25]. This process
involves the formation of immunologic synapse between NK cell
and target cell [26,27]. During the synapse formation, there is a
rapid reorganization of the NK cell cytoskeleton including the
reorientation of the Golgi complex and the microtubule-
organizing center (MTOC) as well as the remodeling of actin
cytoskeleton [28–30].
As opposed to NK cell cytotoxicity, the signaling events that
regulate macrophage mediated ADCC are yet to be character-
ized. The aim of this study was to identify the signaling
pathways that play a crucial role in macrophage response to
antibody-coated tumor cells. For this purpose, we have used
Rituximab-coated human Burkitt’s B cell lymphoma cell line
Raji cells as tumor targets. Rituximab is a human-mouse
chimeric monoclonal antibody specific for CD20 antigen
expressed on B cells. Rituximab has been shown to be effective
in the treatment of various forms of B cell malignancies
including the aggressive and indolent B cell non-Hodgkin’s
lymphoma (NHL) as well as B-cell chronic lymphocytic leukemia
(CLL) [31]. We demonstrate a critical role for the PtdIns 3-
kinase/Akt pathway in macrophage mediated ADCC against
tumor cells. We first show that IFNc primed macrophages
mediate Rituximab-dependent killing of B cell lymphoma. The
interaction of macrophages with antibody-coated tumor targets
leads to the activation of multiple signaling events including the
activation of tyrosine kinases and PtdIns 3-kinase/Akt. Pharma-
cological inhibition of PtdIns 3-kinase/Akt completely abolished
macrophage cytotoxicity indicating that the activation of PtdIns
3-kinase/Akt is critical for macrophage cytotoxicity. Consistent
with this, murine peritoneal macrophages expressing overactive
Akt (Myr-Akt) showed significantly enhanced ADCC compared
to their wild-type counterparts. Further analysis of the role of
the PtdIns 3-kinase/Akt pathway in macrophage ADCC reveals
that this pathway regulates macrophage cytotoxicity at the level
of conjugate formation between the effector macrophages and
antibody-coated tumor cells.
Materials and Methods
Cells, antibodies and reagents
Raw 264.7 cells and Raji cells were obtained from American
Type Culture Collection (Manassas, VA) and maintained in RPMI
1640 supplemented with 5% fetal bovine serum. Recombinant
mouse IFNc and TNFa neutralizing antibody were purchased
from R&D systems (Minneapolis, MN). All phospho-specific
antibodies were from Cell Signaling Technology (Danvers, MA),
iNOS antibody was from BD Transduction laboratories (Franklin
Lakes, NJ), mouse anti-human CD37 antibody was from BD
Biosciences and actin antibody was from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Rituximab and Herceptin antibodies were
produced by Genentech (San Francisco, CA). All pharmacological
inhibitors were purchased from Calbiochem. Griess Reagent kit
was from Molecular Probes (G-7921) (Eugene, OR). Goat anti-
mouse Alexa Fluor 594 and FITC-phalloidin were purchased from
Molecular probes. TNFa ELISA kit was purchased from R&D
systems.
Isolation of peritoneal macrophages
Transgenic mice with macrophage-specific expression of Myr-
Akt have been described earlier [32]. Peritoneal macrophages
from transgenic mice and their wild-type littermates were induced
by i.p. injection of 1.5 ml of 2.9% Brewer’s thioglycolate broth.
Macrophages were harvested 4–5 days post-injection by peritoneal
lavage using RPMI supplemented with 10% FBS. RBCs were
lysed by incubating peritoneal exudate cells with 3–5 ml of RBC
lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA
[pH 8.0]) for 3 minutes on ice.
ADCC assay: A
51Cr-release assay was performed as described
elsewhere [33] with some modifications. Macrophages were plated
in 96-well V-bottom tissue culture plates in 10% RPMI medium
supplemented with mIFNc (25 ng/ml) and incubated overnight at
37uC. Raji cells were labeled with
51Cr followed by coating with
Rituximab. Rituximab was used at a final concentration of 10 mg/
ml in all assays except those where dose response with Rituximab
was measured. Rituximab-coated,
51Cr-labeled Raji targets were
added to macrophages at various E:T ratios. After 8 hours
incubation at 37uC, supernatants were harvested and the amount
of
51Cr released was measured in a gamma counter. The percent
relative cytotoxicity was determined as [(experimental cpm2spon-
taneous cpm)/(total cpm2spontaneous cpm)] *100. For assays
involving inhibitors, IFNc primed macrophages were incubated
with the appropriate inhibitors for 30 minutes before addition of
target cells. Both, L-NMMA, a competitive inhibitor of nitric
oxide production and TNFa neutralizing antibody were added to
macrophage cultures along with IFNc and incubated overnight
before addition of targets.
Preparation of target cells for signaling and cytokine
experiments
Raji cells were first coated with Rituximab (10 mg/ml) at 37uC
for 20 minutes. Unbound antibody was removed by washing cells
once in PBS. Cells were then fixed on ice in 1% paraformaldehyde
(PFA) in PBS for 10 minutes. The cells were finally washed with
PBS thoroughly to remove PFA. Uncoated or control antibody
(Herceptin) treated cells were processed in an identical manner.
Cell stimulation, lysis and Western blotting
Raw 264.7 cells or peritoneal macrophages were plated in 48-
well tissue culture plates and primed with mIFNc (25 ng/ml)
overnight. Cells were then stimulated with fixed Rituximab-coated
or uncoated Raji targets at 1:1 E:T ratio for indicated time points.
Cells were lysed in TN1 lysis buffer (50 mM Tris pH 8.0, 10 mM
EDTA, 10 mM Na4P2O7, 10 mM NaF, 1% Triton-X 100,
125 mM NaCl, 3 mM Na3VO4,1 0mg/ml each aprotinin and
leupeptin). Protein-matched whole cell lysates were separated by
SDS-PAGE, transferred to nitrocellulose membranes, probed with
the antibody of interest and developed with enhanced chemilu-
minescence (ECL).
Western Blot Data Quantitation
The ECL signal was quantitated using a scanner and a
densitometry program (Scion Image; Scion, Frederick, MD).
Background pixel values were subtracted, the signal was
normalized to the amount of actin and the normalized band
intensity values were plotted.
Preparation of heat-aggregated IgG (IgG immune-
complexes)
Heat-aggregated IgG was prepared according to methods
described previously [34]. In brief Chromopure mouse IgG
Regulation of ADCC by PI3K/Akt
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concentration of 350 mg/ml was heated at 62uC for 30 minutes,
then cooled on ice immediately and used to stimulate cells.
Measurement of TNFa by ELISA
Raw 264.7 cells or peritoneal macrophages were incubated with
or without IFNc (25 ng/ml) overnight, treated with DMSO or
10 mM Ly294002 and then stimulated with paraformaldehyde-
fixed Rituximab-coated Raji targets for 8 hours at E:T ratio of 1:1.
The supernatants were harvested and analyzed by ELISA. To test
the neutralizing ability of TNFa blocking antibody, similar
samples were run in parallel in the presence of TNFa blocking
antibody.
Measurement of nitrite by Griess Reagent
The levels of NO were measured by assaying the culture
supernatants for NO2
2, a stable product of NO with molecular
oxygen. The assay was performed with a modification of
previously described method [35] using Griess Reagent kit from
Molecular Probes. For the assay, macrophages were plated in
RPMI containing no phenol red and no serum. To test the effect
of Fc receptor clustering on NO production, macrophages were
primed with IFNc for 16 hours, treated with DMSO or 10 mM
Ly294002 for 30 minutes followed by stimulation with immune-
complexes (350 mg/ml) for 8 hours (IFNc was left in the medium
during immune-complex stimulation). For nitrite assay, 100 mlo f
supernatant was mixed with 50 ml of Griess Reagent (Molecular
Probes G-7921) and incubated at room temperature in dark for
30 minutes. The absorbance was measured at 520 nm and nitrite
concentrations were calculated from a standard curve obtained
using standards containing increasing concentration of NaNO2.
Analysis of conjugate formation
IFNc primed macrophages and Raji tumor cells were stained
for analysis of conjugates using a method described elsewhere [27].
The IFNc primed macrophages were treated with DMSO or
inhibitors (10 mM Ly294002 or 20 nM rapamycin) for 30 minutes
and then mixed with Rituximab-coated Raji cells at 5:1 ratio for
30 minutes at 37uC in suspension. The cell suspension was
transferred to poly-L-lysine coated cover-slips and the plate was
centrifuged at 1600 rpm for 5 minutes. The plate was further
incubated at 37uC for 1 hour. The cells were then fixed using 4%
formaldehyde, washed twice and incubated with mouse anti-
human CD37 antibody overnight followed by Alexa Fluor 594-
conjugated goat anti-mouse for 4 hours. The cells were then
permeabilized using 0.2% Triton-X100 and stained with FITC-
phalloidin.
Cell conjugates were analyzed using Olympus microscope
(Olympus, BX40F-3, Melville, NY) and images were captured
using digital video camera (Olympus U-CMAD-2, Optronics,
Galeta, CA). 100 red cells were analyzed per cover-slip and a total
of 300 red cells per condition were scored for conjugate formation.
The results were expressed as % conjugates formed.
Spreading of macrophages on Rituximab-coated surfaces
The spreading of macrophages on antibody-coated surfaces was
measured as described elsewhere [36]. Thioglycollate-elicited wild-
type peritoneal macrophages were treated with DMSO or 10 mM
Ly294002 for 30 minutes at 37uC. They were then allowed to
spread on cover-slips pre-coated with 1 mg/ml Rituximab for
different time points. The spreading of cells was analyzed using
Nikon E800 microscope and images were captured using a Nikon
FDX-35 camera. The cells were then fixed with 4% formaldehyde.
The surface area occupied by cells was measured using
Morphometry software (version 6) and expressed as arbitrary
units (AU).
Statistical Analysis
All data were analyzed using Student’s t-test and p value of
#0.05 was considered significant.
Results
IFNc-primed macrophages show Rituximab-dependent
lysis of B cell lymphoma Raji cells
We first tested whether macrophages could elicit Rituximab-
dependent killing of B cell lymphoma cells. For this, we used a
standard
51Cr-release assay method which has been extensively
employed by several authors to measure the cytotoxic potential of
NK cells. In these assays, murine macrophages were primed with
IFNc over-night and then co-cultured with
51Cr-labeled, Ritux-
imab-coated Raji cells for 8 hours. The amount of
51Cr released at
the end of 8 hours was measured and is indicated as %
cytotoxicity. First, we analyzed whether murine macrophage cell
line Raw 264.7 and primary peritoneal macrophages could
mediate cytolysis of Rituximab-coated Raji cells. For this, IFNc-
primed macrophages (effectors) were incubated with
51Cr-labeled
Raji cells (targets) coated with Rituximab (10 mg/ml) at different
effector to target (E:T) ratios. Our results indicate that both Raw
264.7 cells and peritoneal macrophages show increasing cytotox-
icity towards Rituximab-coated Raji cells with the increasing E:T
ratio (Figure 1A and 1B).
To confirm that the cytotoxicity seen in the above experiments
is indeed antibody-mediated, IFNc primed Raw 264.7 cells were
incubated with
51Cr-labeled Raji cells coated with increasing
concentration of Rituximab. The results shown in Figure 1C
indicate that there was a dose-dependent increase in the
cytotoxicity mediated by Raw 264.7. Moreover tumor cells not
coated with Rituximab or treated with irrelevant antibody such as
Herceptin which does not bind to Raji cells were not lysed by
IFNc primed macrophages. This indicates that the opsonization
by antibodies that specifically bind the tumor cells induce their
killing by macrophage effectors.
To examine the requirement of priming by IFNc, macrophages
were treated with increasing concentrations of IFNc. As indicated
in Figure 1D, Raw 264.7 cells left untreated with IFNc could not
mediate ADCC while the cytotoxicity of macrophages increased
gradually with increasing doses of IFNc. These data are consistent
with the previously reported requirement of IFNc by macrophages
for tumoricidal activity [14,15].
Rituximab-coated targets induce significant activation of
Syk kinase and the PtdIns 3-kinase/Akt pathway in
macrophages
We investigated the activation of several signaling pathways in
macrophages in response to antibody-coated tumor targets by
stimulating IFNc-primed peritoneal macrophages with formalde-
hyde-fixed Rituximab-coated Raji targets for various time points.
Similar approaches have been used in the past in the studies of NK
cell mediated cytotoxicity [22,23]. Raji cells incubated with
Herceptin (which does not bind to Raji cells) were used as a
control. As shown in Figure 2A upper panel, strong phosphory-
lation of Syk kinase was seen at 30 minutes with Rituximab-coated
targets but not with control antibody-treated targets. The graph
shown in lower panel is a quantitation of band intensity from three
independent experiments. The stimulation of macrophages with
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PtdIns 3-kinase/Akt pathway as seen by serine phosphorylation of
Akt while tumor cells incubated with control antibody failed to
induce Akt activation (Figure 2B). The graph shown in lower panel
represents the average of phospho-Akt band intensity from three
experiments. In addition to the activation of these pathways, we
also observed an increase in phosphorylation of Erk/MAPK with
targets opsonized with Rituximab. No activation of p38 or JNK
MAPKs was seen (data not shown). Collectively, these results
indicate that when macrophages are incubated with tumor cells
coated with the appropriate antibody display the activation of
specific signaling pathways.
Activation of the PtdIns 3-kinase/Akt pathway is critical
for macrophage ADCC
The above experiments demonstrated that there is a significant
activation of the PtdIns 3-kinase/Akt pathway in macrophages
upon ligation with antibody-coated targets. In order to examine
whether the activation of the PtdIns 3-kinase/Akt pathway is
important during cytotoxicity, we used Ly294002, a specific
pharmacological inhibitor of PtdIns 3-kinase. Previous work from
our group has demonstrated that Akt promotes Fc receptor-
mediated phagocytosis through activation of p70S6 kinase
(p70S6K) [32]. To test the requirement of downstream p70S6K
in macrophage mediated ADCC, we incorporated rapamycin, an
inhibitor of mTOR, in this experiment. IFNc primed Raw 264.7
cells were pre-treated with either DMSO or 10 mM Ly294002 or
20 nM rapamycin for 30 minutes. They were then co-cultured
with
51Cr-labeled, Rituximab-coated Raji targets for 8 hours. At
the end of 8 hours, supernatants were harvested and the amount
of
51Cr released was measured. As seen in Figure 3A, pre-
treatment of macrophages with PtdIns 3-kinase inhibitor resulted
in complete inhibition of antibody-dependent cytotoxicity indicat-
ing that the PtdIns 3-kinase/Akt pathway plays a critical role in
macrophage response towards antibody-coated targets. On the
other hand, the cytotoxic ability of macrophages treated with
rapamycin remained unaffected. This suggests that unlike
phagocytosis, activation of p70S6K is dispensable during
FccR-mediated macrophage cytotoxicity. To ensure the speci-
ficity of the inhibitors, Raw 264.7 cells were first incubated with
respective inhibitors for 30 minutes and then stimulated with
immune-complex (heat-aggregated IgG) for 7 minutes. The
protein-matched whole cell lysates were analyzed using phos-
pho-p70S6K antibody for rapamycin and phospho-Akt antibody
for Ly294002. The cells treated with vehicle-control (DMSO)
showed significant induction in phosphorylation of Akt
(Figure 3B, left) and p70S6K (Figure 3B, right) whereas the
treatment of cells with Ly294002 and rapamycin resulted in
Figure 1. IFNc-primed macrophages show Rituximab-dependent lysis of B cell lymphoma Raji cells. A. Raw 264.7 cells or B. peritoneal
macrophages were primed with 25 ng/ml IFNc over-night.
51Cr- labeled Raji cells coated with 10 mg/ml Rituximab were added to IFNc primed
macrophages at E:T ratios of 0:1, 12.5:1, 25:1 and 50:1. The amount of
51Cr released was measured at the end of 8 hours and is shown as %
cytotoxicity. C.
51Cr-labeld Raji cells were coated with increasing concentrations of Rituximab as indicated in the figure or treated with Herceptin
(10 mg/ml). They were then co-cultured with IFNc-primed Raw 264.7 cells for 8 hours. The supernatants were harvested and the amount of
51Cr
released was measured. The graph shows % cytotoxicity values obtained at 50:1 E:T ratio. D. To test the effect of IFNc priming, Raw 264.7 cells were
primed with increasing concentration of IFNc and co-cultured with
51Cr- labeled Rituximab-coated Raji targets for 8 hours. % cytotoxicity values
obtained at the E:T ratio of 50:1 are shown in the graph.
doi:10.1371/journal.pone.0004208.g001
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respectively.
Over-expression of active Akt enhances macrophage
ADCC
The above data indicated that Rituximab-coated Raji cells
stimulate Akt activation in macrophages and activation of PtdIns
3-kinase upstream of Akt is necessary for macrophage ADCC.
Also a previous report from our group has demonstrated that
constitutively active Akt significantly up-regulates FccR-mediated
phagocytosis by macrophages [32]. To determine whether
activation of Akt downstream of PtdIns 3-kinase plays a role
during macrophage mediated ADCC, we tested the cytotoxic
ability of peritoneal macrophages from previously described
transgenic mice over-expressing macrophage specific, constitutive-
ly active Akt (Myr-Akt). The results shown in Figure 4A indicate
that Myr-Akt macrophages show significantly enhanced cytolysis
of Rituximab-coated Raji cells as compared to their wild-type
counterparts. As described previously, there is no difference in the
expression of FccR on the surface of Myr-Akt and wild-type
macrophages [32] indicating that the enhanced ADCC is indeed a
function of over-active Akt and not attributable to the changes in
Fc receptor expression. To confirm the expression of Myr-Akt
transgene, whole cell lysates from wild-type and Myr-Akt
macrophages were resolved on SDS-PAGE and blotted with
phospho-Akt antibody (Figure 4B, upper panel). The lower panel
of Figure 4B is a reprobe of the same membrane with actin
antibody to show equal loading of protein. Together these results
demonstrate that downstream of PtdIns 3-kinase, Akt activation
plays an important role in macrophage response to antibody-
coated tumor cells.
Influence of the PtdIns 3-kinase/Akt pathway on
mediators of cytotoxicity: TNFa and nitric oxide
Several previous studies have indicated that TNFa and nitric
oxide (NO) produced by activated monocytes/macrophages are
predominant effectors of cytotoxicity [7–9]. These studies further
suggest that although many cells are sensitive to TNFa-mediated
lysis, vast majority of the cells appear to be resistant to TNFa-
induced cytolysis [37–40]. Having established the role of the
PtdIns 3-kinase/Akt pathway in macrophage mediated ADCC, we
next wanted to understand the mechanism by which this pathway
regulates cytotoxicity. We hypothesized that the PtdIns 3-kinase/
Akt pathway may enhance macrophage induced tumoricidal
activity by promoting the production of TNFa and/or nitric
oxide.
To test this hypothesis, we measured the amount of TNFa
produced by IFNc-primed macrophages in response to antibody-
coated tumor cells in presence or absence of PtdIns 3-kinase/Akt
inhibitor. For these experiments, Raw 264.7 cells were primed
with IFNc (25 ng/ml) for 16 hours, treated with either DMSO or
10 mM Ly294002 for 30 minutes and then stimulated with
formaldehyde-fixed Rituximab-coated Raji cells at E:T ratio of
1:1 for 8 hours. Raw 264.7 cells left untreated with IFNc,o r
stimulated with IFNc alone or Rituximab-coated Raji cells alone
served as control conditions for the experiment. Supernatants were
harvested and levels of TNFa were measured using ELISA.
Consistent with previous reports, the results shown in Figure 5A
indicate that macrophages primed with IFNc alone produced a
small amount of TNFa [17,41]. Further activation of IFNc-
primed macrophages with antibody-coated tumor cells (indicated
as RR in the figure) resulted in significantly higher levels of TNFa
in presence of DMSO. However, TNFa production stimulated by
Figure 2. Rituximab-coated targets induce significant activation of Syk kinase and the PtdIns 3-kinase/Akt pathway in
macrophages. IFNc-primed peritoneal macrophages were stimulated with paraformaldehyde-fixed Rituximab-coated or control antibody-treated
Raji cells at E:T ratio of 1:1 for indicated time points. Protein-matched whole cell lysates were analyzed by Western blotting with A. phospho-Syk
antibody (upper) and B. phospho-Akt antibody (upper). The same membranes were reprobed with actin antibody (lower). The graphs in the lower
panels show mean and SD of the band intensity of phospho-Syk and phospho-Akt from three independent experiments. Data were analyzed by
student’s t-test (*=p value#0.05).
doi:10.1371/journal.pone.0004208.g002
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inhibited in IFNc primed macrophages treated with Ly294002
indicating that the PtdIns 3-kinase/Akt pathway is involved in
FccR-mediated TNFa production.
As mentioned earlier, majority of tumor cells have been shown
to be resistant to TNFa-mediated lysis [37–40]. Therefore, we
next tested the requirement of TNFa in cytolysis of Rituximab-
opsonized Raji cells by incorporating TNFa neutralizing antibody
in the cytotoxicity assays. As seen in Figure 5B, incubation of
macrophages with TNFa neutralizing antibody had no effect on
their cytotoxic ability towards Rituximab-coated Raji cells
suggesting that Raji cells are resistant to lysis by TNFa. We also
confirmed the blocking activity of TNFa neutralizing antibody in a
parallel experiment using ELISA (data not shown). Thus, although
PtdIns 3-kinase/Akt regulates TNFa production, TNFa is not
required for cytolysis of Raji cells.
Next, we determined the role of NO in macrophage ADCC
against Raji cells. Resting macrophages do not produce nitric
oxide since inducible nitric oxide synthase (iNOS), the enzyme
involved in NO synthesis by macrophages, is not constitutively
expressed [42,43]. However, priming of macrophages with IFNc
induces the expression of iNOS and thereby leads to NO
production [16]. Since L-arginine is used as a substrate by iNOS
for NO synthesis, analogs of L-arginine such as L-NMMA act as
competitive inhibitors of iNOS activity and thereby block NO
production [44]. To examine the role of NO in lysis of Raji cells,
we measured the percent cytotoxicity of macrophages in the
presence of increasing concentrations of L-NMMA. The results
shown in Figure 5C demonstrate that macrophages treated with L-
NMMA lose their cytolytic ability towards Rituximab-coated Raji
cells in a dose-dependent manner. These data demonstrate that
nitric oxide is necessary for lysis of Rituximab-coated Raji cells by
macrophages.
Having established the requirement for NO production, we next
analyzed the role of PtdIns 3-kinase in NO production. Here, Raw
264.7 cells were primed with IFNc (25 ng/ml) alone or further
stimulated by IgG immune-complexes in presence of either
DMSO or 10 mM Ly294002 for 8 hours and the amount of NO
present in supernatants was measured. As shown in Figure 5D,
macrophages when primed with IFNc produced NO. NO
production was further enhanced significantly following the
activation of Fcc receptors by immune-complexes. However,
inhibition of PtdIns 3-kinase/Akt had no effect on the production
of NO upon FccR clustering indicating that PtdIns 3-kinase/Akt
plays no role in FccR-induced NO production by macrophages.
These results can be summarized as follows: a) FccR-mediated
TNFa production is regulated by PtdIns 3-kinase/Akt; however,
TNFa is not involved in lysis of Rituximab-coated Raji cells, b)
Although nitric oxide is required for macrophage ADCC against
Raji cells, activation of PtdIns 3-kinase/Akt does not contribute to
NO synthesis.
The PtdIns 3-kinase/Akt pathway promotes conjugate
formation between macrophages and tumor cells
The above results suggest that an event other than the release of
cytotoxic mediators is a requisite for the cytotoxicity and is
probably influenced by PtdIns 3-kinase/Akt pathway. Many
studies have demonstrated that in the case of NK cell cytotoxicity,
the process of conjugate formation between the effector NK cell
and the target tumor cell is critical and determines the efficacy of
killing [24,25]. The two important events involved in conjugate
formation include reorganization of the actin cytoskeleton and
polarization of microtubule organizing center (MTOC) at the
synapse [28,29,45]. It has been shown that actin remodeling is
required for the maintenance of conjugate formation and also for
the localized release of cytotoxic mediators [46,47]. Several other
reports have demonstrated the role of PtdIns 3-kinase in
cytoskeletal rearrangements [48–50]. We therefore analyzed
whether the loss in macrophage ADCC upon inhibition of PtdIns
3-kinase/Akt was due to defects in conjugate formation with
tumor cells. To visualize the conjugates, we allowed macrophages
(pre-treated with DMSO, Ly294002 or rapamycin) and tumor
cells mixed at E:T ratio of 5:1 to adhere to poly-L-lysine coated
cover-slips. Rituximab-coated Raji tumor cells were then labeled
with mouse anti-human CD37 antibody (a B cell-specific cell
surface marker) followed by goat anti-mouse Alexa Fluor 594 (red
fluorescence) and IFNc primed macrophages were stained with
FITC-phalloidin (green fluorescence). The visualization of actin
polarization at the junction between the macrophage and the
Rituximab-coated Raji cell indicated that DMSO treated
macrophages showed polarization of actin at the synapse formed
with tumor cell, whereas Ly294002 treated macrophages failed to
show significant actin polarization (Figure 6A). To measure the
number of conjugates, 300 tumor cells were counted for each
condition and were scored for conjugate formation. The
Figure 3. Activation of the PtdIns 3-kinase/Akt pathway is
critical for macrophage ADCC. A. IFNc-primed Raw 264.7 cells were
treated with DMSO, 10 mM Ly294002 and 20 nM Rapamycin for
30 minutes. They were then incubated with
51Cr-labeled Rituximab-
coated Raji cells for 8 hours. The graph shows % cytotoxicity at 50:1 E:T
ratio. B. To test the specificity of the inhibitors used, Raw 264.7 cells
were incubated with DMSO, 10 mM Ly294002 or 20 nM Rapamycin for
30 minutes. The cells were then stimulated with immune-complexes for
7 minutes. Protein-matched cell lysates were analyzed by Western
blotting with phospho-Akt antibody and phospho-p70S6K antibody
(upper). R indicates resting samples and A indicates cells activated with
immune-complexes. The same membranes were reprobed with actin
antibody (lower).
doi:10.1371/journal.pone.0004208.g003
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Figure 6B, pre-treatment of macrophages with Ly294002 reduced
their ability to form conjugates with tumor cells. There was no
reduction in percent conjugates formed upon rapamycin treatment.
Similar experiments were performed using peritoneal macrophages
isolated from WT and Myr-Akt mice. Myr-Akt macrophages
displayed significantly increased conjugate formation with anti-
body-coated tumor cells (Figure 6C). These data indicate that the
PtdIns 3-kinase/Akt pathway plays a role in promoting the contact
between macrophages and antibody-coated tumor cells.
The PtdIns 3-Kinase/Akt pathway enhances the
spreading of macrophages on antibody-coated surfaces
As an alternative approach, we analyzed the ability of
macrophages to spread on Rituximab-coated surfaces. Earlier
studies have indicated that spreading of macrophages on human
IgG-coated surfaces involves the insertion of membrane from
intra-cellular source and is dependent upon PtdIns 3-kinase [36].
When we compared the surface area occupied by peritoneal
macrophages treated with DMSO or Ly294002 on Rituximab-
coated surfaces, it was clearly evident that the spreading of
macrophages upon inhibition of PtdIns 3-kinase was restricted to a
significant extent (Figure 7A). The surface area occupied by these
cells was measured using Morphometry software and showed a
significant difference in the areas occupied by DMSO treated cells
as opposed to those treated by Ly294002 (Figure 7B). On the other
hand, Myr-Akt macrophages occupied a significantly greater
surface area as compared to WT macrophages on Rituximab-
coated surfaces (Figure 7C).
Taken together, these findings illustrate that the PtdIns 3-
kinase/Akt pathway plays a critical role in macrophage response
to Rituximab-coated tumor cells at least in part through its
influence on conjugate formation between the macrophages and
the target tumor cells.
Discussion
In this report, we demonstrate that the activation of Akt by
PtdIns 3-kinase plays an important role in macrophage mediated
Figure 4. Over-expression of active Akt enhances macrophage ADCC. A. Wild-type and Myr-Akt expressing peritoneal macrophages were
activated with IFNc over-night.
51Cr- labeled Rituximab-coated Raji targets were added and supernatants harvested at the end of 8 hours. The graph
shows % cytotoxicity values obtained at E:T ratio of 50:1. Data was analyzed using student’s t-test (*=p value#0.05). B. To confirm the expression of
the Myr-Akt transgene, cell lysates from wild-type and Myr-Akt peritoneal macrophages were analyzed by Western blotting with phospho-Akt
antibody (upper). The same membrane was reprobed with actin antibody (lower).
doi:10.1371/journal.pone.0004208.g004
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Akt pathway was found to be required for efficient conjugate
formation as well as spreading of macrophages on antibody-coated
surfaces. In the case of NK cells, studies have shown that conjugate
formation is a critical step for the lysis of tumor cells [24,25]. Our
findings similarly indicate that cytoskeletal rearrangements and
thereby conjugate formation constitute a pre-requisite for effective
cytolysis of antibody-coated tumor cells by monocytes/macro-
phages as well.
PtdIns 3-kinase regulates a diverse array of cellular activities
such as cell growth, survival, cytoskeletal changes and trafficking of
intra-cellular organelles. The activation of PtdIns 3-kinase leads to
changes in the actin cytoskeleton through the activation of various
downstream proteins. PtdIns 3-kinase-dependent activation of Vav
leads to the activation of Rac1 which has been shown to be
involved in actin reorganization [51,52]. During FccR-mediated
phagocytosis, our group has demonstrated that activation of Akt
downstream of PtdIns 3-kinase up-regulates phagocytic process
through the activation of p70S6 kinase [32]. Arf6 is reported to be
essential for actin assembly during FccR-mediated phagocytosis as
well as for NK cell ADCC and the activation of Arf6 depends on
PtdIns 3-kinase [26,53]. Further it has been shown that PtdIns 3-
kinase activity is also involved in the regulation of membrane
availability during engulfment of large size particles [36,54]. In this
report, we show that PtdIns 3-kinase activation during macro-
phage response to antibody-coated tumor cells leads to the
activation of Akt and thereby regulates the cytotoxic response at
least in part by promoting effective contact between macrophages
and tumor cells. In addition to the activation of Akt, PtdIns 3-
kinase may also be involved in the regulation of monocyte/
macrophage cytotoxicity through its influence on other proteins
involved in actin remodeling as discussed earlier. Further studies
Figure 5. Influence of the PtdIns 3-kinase/Akt pathway on mediators of cytotoxicity: TNFa and nitric oxide. A. Raw 264.7 cells were left
untreated or treated with IFNc for 16 hours. They were then incubated with DMSO or 10 mM Ly294002 for 30 minutes followed by stimulation with
Rituximab-coated Raji cells (indicated as RR in the figure) at E:T ratio of 1:1 for 8 hours. Controls conditions consisted of Raw 264.7 cells stimulated
with media alone (UT) or IFNc (25 ng/ml) alone or Rituximab-coated Raji cells alone. Supernatants were harvested and levels of TNFa were measured
using ELISA. B. Raw 264.7 cells were cultured in presence of IFNc and increasing concentrations of TNFa neutralizing antibody (0–1.6 mg/ml) or
control antibody (1.6 mg/ml). After 16 hours of IFNc priming,
51Cr- labeled Rituximab-coated Raji targets were added to Raw 264.7 cells and
incubated for 8 hours. The graph shows % cytotoxicity at E:T ratio of 50:1. C. Raw 264.7 cells were primed with IFNc in presence of varying
concentrations of L-NMMA (0–10 mM). Next day
51Cr- labeled Rituximab-coated Raji targets were added and amount of
51Cr released was measured
at the end of 8 hours. The graph shows % cytotoxicity at E:T ratio of 50:1. D. Raw 264.7 cells were pre-treated with IFNc (25 ng/ml) for 16 hours. They
were then stimulated with immune-complex (indicated as IC in the figure) at concentration of 350 mg/ml for 8 hours in presence of DMSO or 10 mM
Ly294002. Controls conditions consisted of Raw 264.7 cells cultured with media alone (UT) or IFNc (25 ng/ml) alone. Supernatant were harvested at
the end of 24 hours and levels of NO produced were measured.
doi:10.1371/journal.pone.0004208.g005
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with respect to these pathways.
The role of PtdIns 3-kinase during actin remodeling is well
established. However, few studies report the involvement of Akt as
a modulator of cytoskeletal changes. Studies in chicken embryonic
fibroblasts indicated that activation of Akt by PtdIns 3-kinase
induced actin reorganization promoting cell migration [55]. In the
same study, authors demonstrated that constitutive activation of
Akt was sufficient to activate actin assembly and resulted in
increased cell migration even in the presence of Ly294002. A
previous study from our group showed that constitutively active
Akt increased the phagocytic efficiency of macrophages suggesting
that over-active Akt enhances the cytoskeletal rearrangement [32].
In both studies, it was further demonstrated that Akt stimulates
actin cytoskeleton through p70S6 kinase. Interestingly, our
findings reported here show that inhibition of p70S6K by
rapamycin has no effect on the ability of macrophages to lyse
Rituximab-coated B cells. This suggests that Akt can modulate
actin assembly in other ways. Recently, it has been shown that Akt
directly interacts with actin leading to phoshorylation of actin at
Akt consensus sites in Ly294002-dependent manner [56]. Akt has
been shown to associate with and phosphorylate yet another
protein involved in actin remodeling called Girdin [57].
IFNc is known to be a potent activator of macrophage
tumoricidal activities [14,15]. The treatment of macrophages with
IFNc has been reported to stimulate TNFa and nitric oxide
production by macrophages [16,17]. Our data indicate that
activation of FccR upon IFNc priming results in enhanced TNFa
and nitric oxide production. Fc receptor clustering is known to
induce TNFa production even in absence of IFNc priming. Thus
synergistic increase in TNFa production upon co-stimulation with
IFNc and antibody-coated tumor cells was not surprising.
However, to our knowledge, this is the first report demonstrating
enhanced NO production by IFNc-primed macrophages when
stimulated further by immune-complexes.
The inability of IFNc-primed macrophages to lyse B cells in the
absence of antibody opsonization (Figure 1C) has several
implications. It indicates that FccR clustering on macrophages
by Rituximab-coated B cells is an important event and contributes
to the conjugate formation with tumor cells. The priming of
macrophages by IFNc alone leads to the production of nitric
oxide, which is essential for the cytotoxicity towards B cells.
However, mere release of nitric oxide is not sufficient for cytolysis
of B cells if they are not occupied by a specific antibody. The
activation of the PtdIns 3-kinase/Akt pathway by antibody-
coated tumor cells results in stable ligation of tumor cells with
Figure 6. The PtdIns 3-kinase/Akt pathway promotes conjugate formation between macrophages and tumor cells. A. Raw 264.7 cells
were primed with IFNc overnight followed by treatment with DMSO or 10 mM Ly294002 or 20 nM Rapamycin for 30 minutes. They were then mixed
with Rituximab-coated Raji cells at the E:T ratio of 5:1 and adhered to poly-L-lysine coated cover-slips for 1 hour. Raji cells were labeled with CD37
antibody followed by anti-mouse Alexa Fluor 594 (red fluorescence). F-actin was labeled with FITC-phalloidin. Stained cells were observed under the
microscope for action polarization at the synapse. B. Samples were processed as described in A. 100 red cells were analyzed per cover-slip and a total
of 300 red cells per condition were scored for conjugate formation. The results were expressed as % conjugates formed. The data indicate %
conjugates formed in one experiment. Similar results were obtained in three independent experiments. C. Conjugate formation by WT and Myr-Akt
expressing peritoneal macrophages was determined by processing the samples as described in A and B.
doi:10.1371/journal.pone.0004208.g006
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oxide.
Collectively our findings demonstrate a critical role for the
PtdIns 3-kinase/Akt pathway in macrophage-mediated cytotoxic-
ity against Rituximab-coated B cell lymphomas. We show that the
PtdIns 3-kinase/Akt pathway is required for occupation of greater
surface areas on antibody-coated surfaces. Moreover, the forma-
tion of efficient cytolytic synapse between macrophages and
Rituximab-coated B cells is completely dependent upon the PtdIns
3-kinase/Akt pathway.
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